4.7 Article

Fluoroquinolones induce the expression of patA and patB, which encode ABC efflux pumps in Streptococcus pneumoniae

Journal

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 65, Issue 10, Pages 2076-2082

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/jac/dkq287

Keywords

resistance; induction; ABC transporters; DNA damaging agents

Funding

  1. Region Wallonne, Belgium
  2. Coris BioConcept, Gembloux
  3. Belgian Fonds de la Recherche Scientifique Medicale (FRSM) [3.4.597.06]

Ask authors/readers for more resources

Active efflux is a common mechanism of resistance to fluoroquinolones in Streptococcus pneumoniae. Two efflux systems have been described so far in this species: PmrA, a member of the major facilitator superfamily; and the two ABC transporters PatA and PatB. We studied the inducibility of expression of pmrA, patA and patB by using subinhibitory concentrations of fluoroquinolones. A wild-type susceptible strain, two clinical isolates resistant to fluoroquinolones and two efflux mutants selected in vitro after exposure to ciprofloxacin were studied. MICs were determined for these strains and their mutants in which pmrA, patA or patB had been disrupted. Gene expression was determined after exposure to half the MIC of norfloxacin, ciprofloxacin, levofloxacin, moxifloxacin or gemifloxacin and quantified by real-time PCR. Increased MICs of norfloxacin, ciprofloxacin and levofloxacin (to a lesser extent) and increased expression of patA and patB were seen for all resistant strains; these were reduced in patA or patB disruptants or in the presence of reserpine. Exposure to any of the five fluoroquinolones caused a reversible increase in expression of patA and patB, but not of pmrA. Mitomycin C, an inducer of the competence system in S. pneumoniae, also induced patA and patB expression in the two strains tested. The ABC efflux system PatA/PatB is induced upon exposure to subinhibitory concentrations of fluoroquinolones, whether substrates of the transporter or not. This effect, possibly resulting from the activation of the competence pathway, may contribute to resistance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Infectious Diseases

Clinical management of severe infections caused by carbapenem-resistant gram-negative bacteria: a worldwide cross-sectional survey addressing the use of antibiotic combinations

Elena Carrara, Alessia Savoldi, Laura J. Piddock, Francois Franceschi, Sally Ellis, Mike Sharland, Adrian John Brink, Patrick N. A. Harris, Gabriel Levy-Hara, Anusha Rohit, Constantinos Tsioutis, Hiba Zayyad, Christian Giske, Margherita Chiamenti, Damiano Bragantini, Elda Righi, Anna Gorska, Evelina Tacconelli

Summary: The optimal treatment for carbapenem-resistant Gram-negative bacteria infections varies globally, with dual combination therapy being the preferred treatment scheme. However, there is disagreement among clinicians regarding the definition of 'combination therapy.'

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Article Immunology

A Nonprofit Drug Development Model Is Part of the Antimicrobial Resistance AMR Solution

Laura J. Piddock, Jean-Pierre Paccaud, Seamus O'Brien, Michelle Childs, Rohit Malpani, Manica Balasegaram

Summary: Antibiotics are crucial for modern medicine, but commercial developers do not see sufficient profitability to address public need. Nonprofit research and development organizations have the potential to collaborate and provide new antibiotics.

CLINICAL INFECTIOUS DISEASES (2022)

Editorial Material Infectious Diseases

BSAC Vanguard Report Series: The future of drug development

Laura J. Piddock

Summary: The discovery of antibiotics revolutionized medicine, but now antimicrobial resistance is becoming a greater problem than the development of new antimicrobials. New political and economic models are needed to address this escalating crisis. This article examines the challenges and proposes strategies to overcome them.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Article Infectious Diseases

Absence, loss-of-function, or inhibition of Escherichia coli AcrB does not increase expression of other efflux pump genes supporting the discovery of AcrB inhibitors as antibiotic adjuvants

Maria Laura Ciusa, Robert L. Marshall, Vito Ricci, Jack W. Stone, Laura J. Piddock

Summary: The study found that inhibiting the AcrB efflux pump in Escherichia coli did not significantly increase the expression of other efflux pump genes, indicating that there is no compensatory mechanism to overcome efflux inhibition.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Article Chemistry, Medicinal

The polyamino-isoprenyl potentiator NV716 revives disused antibiotics against Gram-negative bacteria in broth, infected monocytes, or biofilms, by disturbing the barrier effect of their outer membrane

Gang Wang, Jean-Michel Brunel, Hector Rodriguez-Villalobos, Jean-Michel Bolla, Francoise Van Bambeke

Summary: NV716 can enhance the activity of antibiotics against difficult-to-treat Gram-negative bacteria by interacting with the bacterial outer membrane, resulting in increased accumulation of antibiotics inside bacteria. It can also increase the activity of antibiotics against intracellular infection and biofilms, without toxicity to eukaryotic cells at sub-MIC concentrations.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Infectious Diseases

Antibiotic Usage in Patients Having Undergone Caesarean Section: A Three-Level Study in Benin

Angele Modupe Dohou, Valentina Oana Buda, Loconon Achille Yemoa, Severin Anagonou, Francoise Van Bambeke, Thierry Van Hees, Francis Moise Dossou, Olivia Dalleur

Summary: The excessive use and misuse of antibiotics have a significant impact on the global numbers of antibiotic-resistant pathogens and commensal bacteria. In Benin, there are various problems with antibiotic use during caesarean sections, highlighting the need for a national policy to improve antibiotic usage.

ANTIBIOTICS-BASEL (2022)

Article Infectious Diseases

Healthcare Professionals' Knowledge and Beliefs on Antibiotic Prophylaxis in Cesarean Section: A Mixed-Methods Study in Benin

Angele Modupe Dohou, Valentina Oana Buda, Severin Anagonou, Francoise Van Bambeke, Thierry Van Hees, Francis Moise Dossou, Olivia Dalleur

Summary: A low adherence to recommendations on antibiotic prophylaxis has been reported worldwide. In Benin, despite the provision of free kits containing necessary supplies and antibiotics for prophylaxis during cesarean sections, the level of antibiotic prophylaxis achievement remains low. A study in three hospitals found that healthcare professionals had limited knowledge and various determinants, such as suboptimal patient health status, low confidence in antibiotics, disagreement with the policy, inappropriate infrastructures and limited financial resources, poor management of the policy at the central level, and patient refusal to buy antibiotics, explain the poor practices. Policymakers must consider these determinants to improve antibiotic prophylaxis and reduce antimicrobial resistance.

ANTIBIOTICS-BASEL (2022)

Article Infectious Diseases

Population Pharmacokinetics of Temocillin Administered by Continuous Infusion in Patients with Septic Shock Associated with Intra-Abdominal Infection and Ascitic Fluid Effusion

Perrin Ngougni Pokem, Xavier Wittebole, Christine Collienne, Hector Rodriguez-Villalobos, Paul M. Tulkens, Laure Elens, Francoise Van Bambeke, Pierre-Francois Laterre

Summary: This study investigated the pharmacokinetics of temocillin in plasma and ascitic fluid, and performed dosing simulations. The current dosing regimen achieved the target concentration in plasma, but not in ascitic fluid. Adjusting the dosing regimen might allow for target concentration attainment in ascitic fluid, but further evaluation is needed for safety and efficacy.

ANTIBIOTICS-BASEL (2022)

Article Infectious Diseases

EnvR is a potent repressor of acrAB transcription in Salmonella

Jessica M. A. Blair, Pauline Siasat, Helen E. McNeil, Abigail Colclough, Vito Ricci, Amelia J. Lawler, Hind Abdalaal, Michelle M. C. Buckner, Alison Baylay, Stephen J. Busby, Laura J. Piddock

Summary: In this study, it was found that EnvR is a potent repressor of acrAB transcription in Salmonella, and can override binding by RamA, thus preventing multidrug resistance to clinically useful drugs. Finding novel tools to increase EnvR expression may form the basis of a new way to prevent or treat multidrug-resistant infections.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Editorial Material Infectious Diseases

An interview with Laura Piddock- by Felicity Poole, commissioning editor

Laura Piddock

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2023)

Correction Microbiology

Hydrolytic Enzymes as Potentiators of Antimicrobials against an Inter-Kingdom Biofilm Model (vol 10, e02589-21, 2022)

Albert Ruiz-Sorribas, Herve Poilvache, Nur Hidayatul Nazirah Kamarudin, Annabel Braem, Francoise Van Bambeke

MICROBIOLOGY SPECTRUM (2023)

Article Microbiology

Mapping direct and indirect MarA/SoxS/Rob/RamA regulons in Salmonella Typhimurium reveals repression of csgD and biofilm formation

Alistair D. Middlemiss, James R. J. Haycocks, Anne M. Stringer, Laura J. V. Piddock, Joseph T. Wade, David C. Grainger

Summary: The transcription factors MarA, SoxS, Rob and RamA control overlapping stress responses in enteric bacteria and their constitutive expression is linked to antibiotic resistance. The study mapped the binding sites of these factors across the Salmonella Typhimurium genome and identified changes in transcription start sites. This information helps disentangle direct and indirect gene regulation effects and deduce promoter architecture within the regulon. The control of csgD, which is involved in biofilm formation, is particularly sensitive to SoxS repression in Salmonella Typhimurium unlike in Escherichia coli where MarA indirectly regulates csgD expression.

MICROBIOLOGY (2023)

Editorial Material Infectious Diseases

Editorial for the Special Issue A Themed Issue in Honor of Professor Hartmut Derendorf-Outstanding Contributions in the Fields of Quantitative Clinical Pharmacology

Francoise Van Bambeke, Sebastian Wicha, Paul M. Tulkens, Markus Zeitlinger

ANTIBIOTICS-BASEL (2023)

Article Infectious Diseases

Exposure of Escherichia coli to antibiotic-efflux pump inhibitor combinations in a pharmacokinetic model: impact on bacterial clearance and drug resistance

Alasdair P. Macgowan, M. L. G. Attwood, Alan R. Noel, R. Barber, Zachary Aron, Timothy J. Opperman, Elizabeth Grimsey, Jack Stone, Vito Ricci, L. J. Piddock

Summary: This study investigated the pharmacodynamic characteristics of efflux pump inhibitors (EPIs) in Escherichia coli through in vitro experiments and gene sequencing. The results showed that the AUC of chlorpromazine and PA beta N was most closely related to the reduction in bacterial load, while the T > threshold of MBX-4191 was the driver for bacterial load reduction. No changes in population profiles were observed with the combination of ciprofloxacin + EPIs, but mutations were detected in gyrA, gyrB, and marR.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Review Biotechnology & Applied Microbiology

Unrealized targets in the discovery of antibiotics for Gram-negative bacterial infections

Ursula Theuretzbacher, Benjamin Blasco, Maelle Duffey, Laura J. V. Piddock

Summary: Advances in genomics, systems biology, protein structure determination, and artificial intelligence provide new opportunities for target-based antibacterial drug discovery. Multiple criteria, including target essentiality, conservation, homology with human genes, and drug-like binding potential, need to be considered in selecting a suitable target. Subcellular location and the risk of drug resistance also play important roles in the process. This review highlights promising targets and inhibitors for Gram-negative bacteria and lessons learned from past drug discovery programs.

NATURE REVIEWS DRUG DISCOVERY (2023)

No Data Available